4 Dividend Stocks to Double Up on Right Now

Source The Motley Fool

You can pat yourself on the back if you're thinking of loading up your portfolio with dividend-paying stocks -- because they're surprisingly strong wealth builders. (If you weren't thinking of doing so, you can start now!)

Dividend payers aren't slouches. They're not sleepy stocks only suitable for grandparents. Plenty of high-performing growth stocks pay dividends -- such as Apple and Nvidia -- and though their dividend yields can be low sometimes, they can also be fast-growing. When you factor growing dividends into the total returns of slower-growing blue chip companies, they become much more compelling.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

Someone in sunglasses is smiling broadly.

Image source: Getty Images.

To appreciate the power of dividends, check out the eye-opening numbers below, adapted from a Hartford Funds report:

Dividend-Paying Status

Average Annual Total Return, 1973-2023

Dividend growers and initiators

10.19%

Dividend payers

9.17%

No change in dividend policy

6.74%

Dividend non-payers

4.27%

Dividend shrinkers and eliminators

(0.63%)

Equal-weighted S&P 500 index

7.72%

Data source: Ned Davis Research and Hartford Funds.

Here are four dividend payers to consider for your long-term stock portfolio:

1. Pfizer

Pfizer (NYSE: PFE) is a more familiar name than it was a few years ago, before people started lining up to receive Pfizer vaccines for COVID-19. But demand for vaccines has waned now, which has taken some wind out of Pfizer's sails. Still, there's a lot to like about this company.

Its COVID-19 vaccine and the related Paxlovid treatment are still generating more than $8 billion annually, and the company has a significant portfolio of drugs in development and on the market. It's expanded that via acquisition, too, such as how it greatly expanded its oncology business by buying Seagen. Note, too, that companies in the healthcare realm are more defensive than many others as healthcare spending is less optional during economic downturns.

What about Pfizer's dividend? Well, it recently yielded a fat 6.6%! And better still, its shares seem attractively valued, with a recent forward-looking price-to-earnings (P/E) ratio of 8.7, well below the five-year average of 10.7.

2. Medtronic

Medtronic (NYSE: MDT), a giant in medical devices, is another solid dividend payer with a recent yield of 3.2%. That payout has grown at an average annual rate of about 5% over the past five years -- and Medtronic has been upping its payout for 46-some years.

The stock hasn't been a fast grower in recent years, but as with all good dividend payers, investors get paid to wait for stronger-performing years to arrive. There's good reason to hope for that, too, as Medtronic has many new products in the offing, some of which can turn out to be blockbusters. The company recently had more than 190 active clinical trials, and has invested $2.7 billion in research and development for fiscal 2024.

Also, Medtronic's business is fairly defensive, with those needing devices not so likely to put that off. Medtronic's stock price seems quite reasonable at recent levels, too, with its forward P/E of 14.7 well below the five-year average of 17.6.

3. Realty Income

Realty Income (NYSE: O) is a company not everyone may know, but those who do know it are often impressed. It's a real estate investment trust (REIT) -- a company that owns lots of real estate, charging its tenants rent. REITs are required to pay out at least 90% of their taxable earnings as dividends, so they're often good dividend payers.

Realty Income, unlike most dividend payers who pay out quarterly, pays its dividend monthly. In its third quarter earnings report, it announced its 108th consecutive dividend increase. The company recently owned 15,450 properties across 90 different industries leased to more than 1,500 clients throughout all 50 U.S. states and a handful of countries in Europe.

Realty Income is growing well, too, with third-quarter revenue up 28% year over year. This is a dividend payer well worth considering.

4. Schwab U.S. Dividend Equity ETF

Finally, consider the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD). It's an exchange-traded fund (ETF), which is a fund that trades like a stock. It has a solid performance record, averaging annual gains of about 11% over both the past five and 10 years -- while delivering growing dividends. It recently yielded around 3.5% and it held stock in roughly 100 companies.

Buying into a good dividend-focused ETF can save you from having to research and pick individual dividend payers, hoping they'll be great for many years.

Should you invest $1,000 in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $859,342!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of December 23, 2024

Selena Maranjian has positions in Apple, Medtronic, Nvidia, Pfizer, Realty Income, and Schwab U.S. Dividend Equity ETF. The Motley Fool has positions in and recommends Apple, Nvidia, Pfizer, and Realty Income. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
The $589 XRP Dream: Believers Aren’t ‘Delusional’ Enough, Expert SaysA known market analyst sees the $6 per coin prediction for XRP crypto being claimed by some experts as too conservative.
Author  NewsBTC
Dec 17, Tue
A known market analyst sees the $6 per coin prediction for XRP crypto being claimed by some experts as too conservative.
placeholder
Solana whale sbfonchain.sol is back to buying the hottest meme tokensOne of the most widely watched meme token traders, sbfonchain.sol, is back to buying.
Author  Cryptopolitan
Dec 20, Fri
One of the most widely watched meme token traders, sbfonchain.sol, is back to buying.
placeholder
Elon Musk’s D.O.G.E could crash the US economyD.O.G.E isn’t even a real government department. It’s an advisory group. It can’t implement anything without Congress or Trump signing off.
Author  Cryptopolitan
Yesterday 00: 35
D.O.G.E isn’t even a real government department. It’s an advisory group. It can’t implement anything without Congress or Trump signing off.
placeholder
Where Will SoundHound AI Stock Be in 1 Year?SoundHound AI (NASDAQ: SOUN) emerged as one of the hottest technology sector growth stocks on Wall Street. At the time of this writing, shares have skyrocketed an astonishing 870% year to date, powered by mounting market enthusiasm for the company's innovative artificial intelligence (AI) solutions that may just be at the beginning of transformative long-term growth.
Author  The Motley Fool
14 hours ago
SoundHound AI (NASDAQ: SOUN) emerged as one of the hottest technology sector growth stocks on Wall Street. At the time of this writing, shares have skyrocketed an astonishing 870% year to date, powered by mounting market enthusiasm for the company's innovative artificial intelligence (AI) solutions that may just be at the beginning of transformative long-term growth.
placeholder
Fake AI images of Putin’s Dream make a photojournalist lose his fansBelgian photojournalist Carl De Keyzer faced massive criticism after the release of his book Putin’s Dream. He was accused by some of creating false visuals and spreading misinformation because he used generative AI to create the photos. After Russia’s invasion of Ukraine disrupted airspace, Keyzer couldn’t travel anymore and chose to use generative artificial intelligence […]
Author  Cryptopolitan
1 hour ago
Belgian photojournalist Carl De Keyzer faced massive criticism after the release of his book Putin’s Dream. He was accused by some of creating false visuals and spreading misinformation because he used generative AI to create the photos. After Russia’s invasion of Ukraine disrupted airspace, Keyzer couldn’t travel anymore and chose to use generative artificial intelligence […]
goTop
quote